10,124.00p-130.00 (-1.27%)17 Apr 2025, 17:15
Jump to:
Astrazeneca PLC Fundamentals
Company Name | Astrazeneca PLC | Last Updated | 2025-04-17 |
---|---|---|---|
Industry | Drug Manufacturers - General | Sector | Healthcare |
Shares in Issue | 1.550 bn | Market Cap | £156.94 bn |
PE Ratio | 29.77 | Dividend per Share | $2.99 |
Dividend Yield | 2.43 | Dividend Cover | 1.50 |
EPS | $4.50 | EPS Growth (%) | 0.12 |
PEG | 0.95 | DPS Growth (%) | 0.0409 |
Debt Ratio | 0.3008 | Debt Equity Ratio | 0.7366 |
Asset Equity Ratio | n/a | Cash Equity Ratio | n/a |
Quick Ratio | 0.6483 | Current Ratio | 0.93 |
Price To Book Value | 0 | ROCE | 0 |
Astrazeneca PLC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|---|---|---|---|---|
Prelim | 2025-02-20 | 2025-03-24 | GBP | 1.6800 | |
Interim | 2024-08-08 | 2024-09-09 | GBP | 0.7760 | |
Prelim | 2024-02-22 | 2024-03-25 | GBP | 1.5600 | |
Interim | 2023-08-10 | 2023-09-11 | GBP | 0.7180 | |
Prelim | 2023-02-23 | 2023-03-27 | GBP | 1.6280 | |
Interim | 2022-08-11 | 2022-09-12 | GBP | 0.7640 |
Astrazeneca PLC Company Financials
Assets | 2024 | 2023 | 2022 |
---|---|---|---|
Tangible Assets | $11.65 bn | $10.50 bn | $9.45 bn |
Intangible Assets | $58.20 bn | $58.14 bn | $59.13 bn |
Investments | $1.90 bn | $1.68 bn | $1.14 bn |
Total Fixed Assets | $78.21 bn | $76.06 bn | $73.89 bn |
Stocks | $5.29 bn | $5.42 bn | $4.70 bn |
Debtors | $11.23 bn | $10.51 bn | $9.19 bn |
Cash & Equivalents | $5.53 bn | $5.86 bn | $6.24 bn |
Other Assets | $6.46 bn | $5.75 bn | $4.17 bn |
Total Assets | $104.03 bn | $101.12 bn | $96.48 bn |
Liabilities | 2024 | 2023 | 2022 |
---|---|---|---|
Creditors within 1 year | $27.87 bn | $30.54 bn | $26.29 bn |
Creditors after 1 year | $35.30 bn | $31.41 bn | $33.13 bn |
Other Liabilities | 0 | 0 | 0 |
Total Liabilities | $63.16 bn | $61.95 bn | $59.42 bn |
Net assets | $40.87 bn | $39.17 bn | $37.06 bn |
Equity | 2024 | 2023 | 2022 |
---|---|---|---|
Called up share capital | $388.00 m | $388.00 m | $387.00 m |
Share Premium | $35.38 bn | $35.34 bn | $35.31 bn |
Profit / Loss | $8.69 bn | $6.90 bn | $2.50 bn |
Other Equity | $40.79 bn | $39.14 bn | $37.04 bn |
Preference & Minorities | $85.00 m | $23.00 m | $21.00 m |
Total Capital Employed | $40.87 bn | $39.17 bn | $37.06 bn |
Ratios | 2024 | 2023 | 2022 |
---|---|---|---|
Debt Ratio | $0.40 | $0.37 | $0.39 |
Debt-to-Equity | $0.68 | $0.59 | $0.64 |
Assets / Equity | n/a | n/a | n/a |
Cash / Equity | n/a | n/a | n/a |
EPS | $4.62 | $4.11 | $2.51 |
Cash Flow | 2024 | 2023 | 2022 |
---|---|---|---|
Cash from operating activities | $11.86 bn | $10.35 bn | $9.81 bn |
Cashflow before financing | $7.87 bn | $3.78 bn | $2.98 bn |
Increase in Cash | -$115.00 m | -$286.00 m | $25.00 m |
Income | 2024 | 2023 | 2022 |
---|---|---|---|
Turnover | $54.07 bn | $45.81 bn | $44.35 bn |
Cost of sales | $10.21 bn | $8.27 bn | $12.39 bn |
Gross Profit | $43.87 bn | $37.54 bn | $31.96 bn |
Operating Profit | $10.00 bn | $8.19 bn | $3.76 bn |
Pre-Tax profit | $8.69 bn | $6.90 bn | $2.50 bn |
Astrazeneca PLC Company Background
Sector | Healthcare |
---|---|
Activities | A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales. |
Latest Interim Date | 25 Jul 2024 |
Latest Fiscal Year End Date | 6 Feb 2025 |
Astrazeneca PLC Directors
Appointed | Name | Position |
---|---|---|
2016-12-01 | Mr. Jean-Philippe Courtois | Non-Executive Director |
2010-11-16 | Ms. Michele J. Hooper | Non-Executive Director |
1995-04-11 | Sir Peter Leahy Bonfield CBE | Non-Executive Director |
2019-04-26 | Mr. Rudolph Harold Peter Markham | Non-Executive Director |
2025-02-18 | Ms. Sherilyn S. McCoy | Non-Executive Director |
2010-10-29 | Dr. Jane E Henney, M.D. | Non-Executive Director |
2019-03-07 | Mr. David R. Brennan | Executive Director,Chief Executive Officer |
2025-04-11 | Dr. Andreas Rummelt | Non-Executive Director |
2009-10-30 | Mr. Bo Angelin | Non-Executive Director |
2000-12-22 | Ms. Erna Moller | Non-Executive Director |
2011-11-16 | Dr. Hakan L. Mogren | Non-Executive Director,Deputy Chairman |
2015-04-24 | Dr. John Silvester Varley | Non-Executive Director |
2011-08-09 | Sir Jonathan Richard Symonds CBE | Executive Director,Chief Financial Officer |
2024-02-20 | Mr. Leif Johansson | Non-Executive Director,Chairman |
2012-06-01 | Mr. Louis Schweitzer | Non-Executive Director,Chairman |
2022-02-22 | Mr. Marc Dunoyer | Executive Director,Chief Financial Officer |
2025-02-18 | Mr. Marcus Wallenberg | Non-Executive Director |
2025-02-18 | Mr. Michel Demare | Non-Executive Director,Chairman |
2025-03-07 | Mr. Pascal Soriot | Executive Director,Chief Executive Officer |
2025-02-18 | Mr. Philip A J Broadley | Non-Executive Director,Senior Independent Director |
2014-03-20 | Mr. Simon Jonathan Lowth | Executive Director,Chief Financial Officer |
2011-08-09 | Dr. John Simon Patterson, CBE | Executive Director |
2015-04-24 | Professor Dame Nancy Rothwell | Non-Executive Director |
2005-08-25 | Sir John Buchanan | Non-Executive Director |
2023-02-21 | Mr. Graham Andrew Chipchase, C.B.E. | Non-Executive Director,Senior independent Director |
2023-02-21 | Ms. Genevieve Berger | Non-Executive Director |
2017-11-13 | Dr. Bruce Burlington | Non-Executive Director |
2003-09-08 | Mr. Joe Jimenez | Non-Executive Director |
2019-03-05 | Baroness Shriti Vadera | Non-Executive Director |
2017-04-27 | Ms. Ann Cairns | Non-Executive Director |
2025-02-18 | Ms. Diana Layfield | Non-Executive Director |
2025-04-11 | Ms. Deborah DiSanzo | Non-Executive Director |
2025-02-18 | Ms. Anna Olive Magdelene Manz | Non-Executive Director |
2016-09-30 | Dr. Cornelia Bargmann | Non-Executive Director |
2025-02-18 | Professor Nazneen Rahman | Non-Executive Director |
2025-03-06 | Dr. Aradhana Sarin | Executive Director,Chief Financial Officer |
2025-02-18 | Professor Tony Mok | Non-Executive Director |
2025-02-18 | Dr. Euan Ashley | Non-Executive Director |
Astrazeneca PLC Contact Details
Company Name | AstraZeneca PLC |
---|---|
Address | 2 Kingdom Street, London, W2 6BD |
Telephone | +44 2076048000 |
Website | https://www.astrazeneca.com |
Astrazeneca PLC Advisors
Auditor | KPMG |
---|---|
Phone | +44 2073111000 |
Fax | +44 2073113311 |
Remuneration Consultant | Deloitte LLP |
---|---|
Phone | +44 2079363000 |
Fax | +44 2075831198 |
Financial PR Adviser | Finsbury |
---|---|
Phone | +44 2072513801 |
Fax | +44 2073744133 |
Bank | Citibank |
---|---|
Phone | +44 2075005500 |
Bank | HSBC Bank PLC |
---|
Registrar | Equiniti Ltd. |
---|---|
Phone | +44 1214157082 |
Solicitor | Freshfields Bruckhaus Deringer |
---|---|
Phone | +44 2079364000 |
Fax | +44 2078327001 |
Stockbroker | Goldman Sachs International |
---|---|
Phone | +44 2077741000 |
Stockbroker | Morgan Stanley & Co International PLC |
---|---|
Phone | +44 2074258000 |
Fax | +44 2074258990 |
Auditor | KPMG AUDIT PLC |
---|
Auditor | KPMG LLP |
---|---|
Phone | +1 212 758-9700 |
Fax | +1 212 758-9819 |
Auditor | KPMG Klynveld Peat Marwick Goerdeler SA |
---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine

Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
Company | Price | % Chg |
---|---|---|
Dunelm Group PLC | 1,074.00 | 13.29 |
Asos PLC | 313.50 | 6.63 |
Rentokil Initial PLC | 350.00 | 5.01 |
Sainsbury (J) PLC | 256.80 | 3.55 |
Dr. Martens PLC | 52.80 | 3.53 |
Pershing Square Holdings LTD | 3,414.00 | 3.45 |
Fallers
Company | Price | % Chg |
---|---|---|
Dowlais Group PLC | 51.40 | -6.03 |
Fresnillo PLC | 1,021.00 | -5.55 |
Jupiter Fund Management PLC | 69.30 | -5.07 |
Goodwin PLC | 6,780.00 | -4.51 |
Spectris PLC | 1,987.00 | -4.38 |
Twentyfour Income Fund Limited | 108.60 | -3.89 |
Risers/fallers data from previous trading day.